Today

Agents

Chat

Arena

Discover

More

App

HBM Healthcare says Lilly to buy portfolio company Curevo Vaccine - LLY News | Rallies

HBM Healthcare says Lilly to buy portfolio company Curevo Vaccine

LLY•2026-07-24

HBM Healthcare reports Q1 FY 2026/27 profit

HBM Healthcare Investments reported a CHF 238 million Q1 FY 2026/27 profit, driven by CHF 183 million gains in listed holdings.

Private portfolio gains and new investments

Private portfolio added CHF 105 million, led by Eli Lilly’s planned acquisition of Curevo Vaccine.

IPO-related gains were cited for Parabilis Medicines, a USD 670 million offering, alongside Odyssey Therapeutics.

Dren Bio financing drove a CHF 71 million positive valuation effect.

New private investments included Lycia Therapeutics for USD 9 million and CellCentric for USD 12.5 million.

Related News

Codexis Announces Pricing Of Public Offering Of Common Stock

CDXS•2026-07-24

Galaxy Digital prices $3.51 billion senior secured notes offering due 2031

GLXY•2026-07-24

Pinnacle Financial Partners Inc <PNFP.N>: Raymond James cuts target price to $115 from $120

Sources

D

HBM Healthcare says Lilly to buy portfolio company Curevo Vaccine

Docs

•

2026-07-24

Top apparel exporter Vietnam faces higher U.S. tariffs than peers

NKE•2026-07-24

Roper Technologies Inc <ROP.O>: RBC Raises Target Price to $417 From $407

ROP•2026-07-24